Research Progress of Neoadjuvant Chemotherapy in Advanced Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIZhen-kai ,  DONGMao-sheng

Department of General Surgery, The Second Artillery General Hospital PLA, Beijing 100088, china;

Corresponding?author：

DONGMao-sheng, Email: 13051186112@163.com

Keywords：

Advanced gastric cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy

DOI：

10.7507/1007-9424.20140347

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of neoadjuvant chemotherapy in advanced gastric cancer. Method The literatures about the research progress of neoadjuvant chemotherapy in the advanced gastric cancer were reviewed. Results The neoadjuvant chemotherapy in the advanced gastric cancer could significantly improve the R₀ resection rate, improve the long-term survival rate, and reduce the risk of death.The course of neoadjuvant chemotherapy for locally advanced gastric cancer without distant metastasis generally was 6-9 weeks, and then according to the results of the curative effect evaluation to decide whether to undergo surgery treatment.Further the clinical research and improvement of chemotherapy sensitivity detection method were helpful to the unity of the standard of neoadjuvant chemotherapy. Conclusions The curative effect of neoadjuvant chemotherapy in advanced gastric cancer is clear.But there is no uniform standard on such as indications, chemotherapy regimens, medication time, and curative effect evaluation index, and so on.It is still needed the further research of multicenter and large clinical trials.

Citation： LIZhen-kai, DONGMao-sheng. Research Progress of Neoadjuvant Chemotherapy in Advanced Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(11): 1460-1464. doi: 10.7507/1007-9424.20140347 Copy

1.	?Christoph S, Daniel R, Alexander N.Neoadjuvant treatment for gastric cancer[J].J Gastric Cancer, 2013, 13(2):73-78.
2.	Jemal A, Bray F, Center MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.
3.	左朝暉, 歐陽永忠, 湯明, 等.胃癌的綜合治療研究的進展[J/CD].中華普外科手術學雜志:電子版, 2012, 6(3):319-324.
4.	陳國玉.進展期胃癌的新輔助化療[J].臨床外科雜志, 2005, 13(8):476-477.
5.	Crookes P, Leichman CG, Leichman L, et al.Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy:a final report[J].Cancer, 1997, 79(9):1767-1775.
6.	Lowy AM, Mansfield PF, Leach SD, et al.Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer[J].Ann Surg, 1999, 229(3):303-308.
7.	季加孚.胃腸道腫瘤的新輔助治療[J].中國實用外科雜志, 2005, 25(5):261-263.
8.	Yonemura Y, Elnemr A, Endou Y, et al.Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer[J].Int J Surg Oncol, 2012, 2012:148420.
9.	Matsuda S, Takahashi T, Fukada J, et al.PhaseⅠstudy of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis:KOGC04[J].Radiat Oncol, 2014, 9:9.
10.	陳志新, 張波.胃癌綜合治療現狀及展望[J].中國普外基礎與臨床雜志, 2008, 15(1):71-73.
11.	Teng RY, Zhou JC, Jiang ZN, et al.The relationship between Lin28 and the chemotherapy response of gastric cancer[J].Onco Targets Ther, 2013, 6:1341-1345.
12.	Frei E.Clinical cancer research:an embattled species[J].Cancer, 1982, 50(10):1979-1992.
13.	Wilke H, Preusser P, Fink U, et al.Preoperative chemotherapy in locally advanced and nonresectable gastric cancer:a phaseⅡstudy with etoposide, doxorubicin, and cisplatin[J].J Clin Oncol, 1989, 7(9):1318-1326.
14.	Plukker JT, Mulder NH, Sleijfer DT, et al.Chemotherapy and surgery for locally advanced cancer of the cardia and fundus:phaseⅡstudy with methotrexate and 5-fluorouracil[J].Br J Surg, 1991, 78(8):955-958.
15.	Mai M, Takahashi Y, Fujimoto T, et al.Neoadjuvant chemotherapy for far-advanced gastric carcinoma[J].Gan To Kagaku Ryoho, 1994, 21(4):431-439.
16.	Wilke H, Stahl M, Fink U, et al.Preoperative chemotherapy for unresectable gastric cancer[J].World J Surg, 1995, 19(2):210-215.
17.	Kang YK, Choi DW, Im YH, et al.A phaseⅢrandomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer[J].Proc Am Soc Clin Oncol, 1996, 15:Abstract 503.
18.	Earle CC, Maroun JA.Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients:Revisiting a meta-analysis of randomised trials[J].Eur J Cancer, 1999, 35(7):1059-1064.
19.	Songun I, Keizer HJ, Hermans J, et al.Chemotherapy for operable gastric cancer:results of the Dutch randomised FAMTX trial.The Dutch Gastric Cancer Group (DGCG)[J].Eur J Cancer, 1999, 35(4):558-562.
20.	Fujii M, Kosaki G, Tsuchiya S, et al.Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer[J].Proc Am Soc Clin Oncol, 1999, 18:Abstract 1045.
21.	Kollmannsberger C, Quietzsch D, Haag C, et al.A phaseⅡstudy of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer[J].Br J Cancer, 2000, 83(4):458-462.
22.	Gianni L, Panzini I, Tassinari D, et al.Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer[J].Ann Oncol, 2001, 12(8):1179-1180.
23.	Schuhmacher CP, Fink U, Becker K, et al.Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum.Closing results after 5 years of follow-up[J].Cancer, 2001, 91(5):918-927.
24.	Piessen G, Messager M, Le Malicot K, et al.PhaseⅡ/Ⅲmulticentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomasPRODIGE 19-FFCD1103-ADCI002[J].BMC Cancer, 2013, 13:281.
25.	Mirza A, Pritchard S, Welch I.The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas[J].Int J Surg Oncol, 2013, 2013:781742.
26.	Basi A, Sohrabkhani S, Zamani F, et al.Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer[J].Int J Hematol Oncol Stem Cell Res, 2013, 7(4):24-28.
27.	Schuhmacher C, Gretschel S, Lordick FA, et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European organisation for research and treatment of cancer randomized trial 40954[J].J Clin Oncol, 2010, 28(35):5210-5218.
28.	Allum W, Cunningham D, Weeden S, et al.Perioperative chemotherapy in operable gastric and lower oesophageal cancer:A randomised, controlled trial (the MAGIC trial, ISRCTN 93793971)[J].Proc Am Soc Clin Oncol, 2003, 22:Abstract 998.
29.	Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med, 2006, 355(1):11-20.
30.	Cunningham D, Rao S, Starling N, et al.Randomised multicentre phaseⅢstudy comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer:The REAL 2 trial[J].J Clin Oncol (Meeting Abstracts), 2006, 24(18_suppl):LBA4017.
31.	Du Y, Cheng XD, Xu ZY, et al.D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction[J].Chin J Cancer Res, 2013, 25(4):479-481.
32.	季加孚, 季鑫.胃癌新輔助化療的現狀與展望[J].中國腫瘤臨床, 2012, 39(20):1458-1461.
33.	肖鳳, 劉彬, 高紅英, 等.進展期胃癌新輔助化療療效的Meta分析[J].重慶醫學, 2012, 41(25):2591-2594.
34.	Chen WJ, Shen J, Pan T, et al.FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer[J].Exp Ther Med, 2014, 7(2):461-467.
35.	Zhao Q, Li Y, Tian Y, et al.Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma[J].Hepato-gastroenterology, 2013, 60(123):638-640.
36.	李濤, 馮道夫, 梁美霞, 等.進展期胃癌應用SOX方案新輔助化療對腫瘤TNM分期的影響[J].世界華人消化雜志, 2014, 22(2):249-252.
37.	劉林, 楊新輝, 王海江, 等.多西他賽聯合奧沙利鉑及替吉奧治療進展期胃癌的療效及對圍手術期影響[J].中國腫瘤臨床, 2014, 40(13):788-791.
38.	Yoshikawa T, Rino Y, Yukawa N, et al.Neoadjuvant chemotherapy for gastric cancer in Japan:a standing position by comparing with adjuvant chemotherapy[J].Surg Today, 2014, 44(1):11-21.
39.	沈琳.進展期胃癌新輔助化療研究與實踐[J].外科理論與實踐, 2008, 13(1):21-23.
40.	Arkenau HT, Saggese M, Lemech C.Advanced gastric cancer:is there enough evidence to call second-line therapy standard?[J].World J Gastroenterol, 2012, 18(44):6376-6378.
41.	Shrikhande SV, Barreto SG, Talole SD, et al.D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy[J].World J Surg Oncol, 2013, 11:31.
42.	Ninomiya Y, Yanagisawa A, Kato Y, et al.Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy[J].J Cancer Res Clin Oncol, 1999, 125(12):699-706.
43.	Becker K, Mueller JD, Schulmacher C, et al.Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J].Cancer, 2003, 98(7):1521-1530.
44.	Ott K, Weber WA, Lordick F, et al.Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction[J].J Clin Oncol, 2006, 24(29):4692-4698.
45.	Lordick F, Ott K, Krause BJ, et al.PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:the MUNICON phaseⅡtrial[J].Lancet Oncol, 2007, 8(9):754-755.
46.	Zhang CH, Li GL, Fan CG, et al.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer[J].World J Surg Oncol, 2012, 10:162.
47.	An JY, Kim HI, Cheong JH, et al.Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy[J].Yonsei Med J, 2013, 54(4):888-894.
48.	Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment[J].Cancer, 1981, 47(1):207-214.
49.	Therasse P, Arbuck SG, Eisenhauer EA, et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J].J Natl Cancer Inst, 2000, 92(3):205-216.
50.	Japanese Gastric Cancer Association.Japanese classification of gastric carcinoma 2nd English edition:response assessment of chemotherapy and radiotherapy for gastric carcinoma:clinical criteria[J].Gastric Cancer, 2001, 4(1):1-8.
51.	Choi H, Charnsangavej C, Faria SC, et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:Proposal of new computed tomography response criteria[J].J Clin Oncol, 2007, 25(13):1753-1759.
52.	Yun M, Lim JS, Noh SH, et al.Lymph node staging of gastric cancer using 18F-FDG PET:a comparison study with CT[J].J Nucl Med, 2005, 46(10):1582-1588.
53.	Kwee RM, Kwee TC.Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer[J].World J Gastroenterol, 2014, 20(7):1650-1656.
54.	Schuhmacher C, Reim D, Novotny A.Neoadjuvant treatment for gastric cancer[J].J Gastric Cancer, 2013, 13(2):73-78.
55.	嚴超, 朱正綱, 燕敏, 等.內鏡超聲檢查和多層螺旋CT對胃癌淋巴結轉移狀況的評估價值[J].中華外科雜志, 2005, 43(3):174-176.
56.	Hwang SW, Lee DH, Lee SH, et al.Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography[J].J Gastroenterol Hepatol, 2010, 25(3):512-518.
57.	Napieralski R, Ott K, Kremer M, et al.Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients[J].Clin Cancer Res, 2005, 11(8):3025-3031.
58.	Ott K, Vogelsang H, Marton N, et al.The thymidylate synthase tandem repeat promoter polymorphism:A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer[J].Int J Cancer, 2006, 119(12):2885-2894.
59.	Nio Y, Koike M, Omori H, et al.A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study[J].Anticancer Res, 2004, 24(3b):1879-1887.
60.	Kang Y, Ohtsu A, Van Cutsem E, et al.AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)[J].J Clin Oncol (Meeting Abstracts), 2010, 28(18_suppl):LBA4007.
61.	王震, 陳俊強.進展期胃癌新輔助化療相關研究的新進展[J].中國普通外科雜志, 2012, 21(4):456-461.
62.	Lorenzen S, Blank S, Becker K, et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol, 2011, 29(15, S):2119-2127.
63.	Kurokawa Y, Shibata T, Sasako M, et al.Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A)[J].Gastric Cancer, 2014, 17(3):514-521.

1. ?Christoph S, Daniel R, Alexander N.Neoadjuvant treatment for gastric cancer[J].J Gastric Cancer, 2013, 13(2):73-78.
2. Jemal A, Bray F, Center MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.
3. 左朝暉, 歐陽永忠, 湯明, 等.胃癌的綜合治療研究的進展[J/CD].中華普外科手術學雜志:電子版, 2012, 6(3):319-324.
4. 陳國玉.進展期胃癌的新輔助化療[J].臨床外科雜志, 2005, 13(8):476-477.
5. Crookes P, Leichman CG, Leichman L, et al.Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy:a final report[J].Cancer, 1997, 79(9):1767-1775.
6. Lowy AM, Mansfield PF, Leach SD, et al.Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer[J].Ann Surg, 1999, 229(3):303-308.
7. 季加孚.胃腸道腫瘤的新輔助治療[J].中國實用外科雜志, 2005, 25(5):261-263.
8. Yonemura Y, Elnemr A, Endou Y, et al.Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer[J].Int J Surg Oncol, 2012, 2012:148420.
9. Matsuda S, Takahashi T, Fukada J, et al.PhaseⅠstudy of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis:KOGC04[J].Radiat Oncol, 2014, 9:9.
10. 陳志新, 張波.胃癌綜合治療現狀及展望[J].中國普外基礎與臨床雜志, 2008, 15(1):71-73.
11. Teng RY, Zhou JC, Jiang ZN, et al.The relationship between Lin28 and the chemotherapy response of gastric cancer[J].Onco Targets Ther, 2013, 6:1341-1345.
12. Frei E.Clinical cancer research:an embattled species[J].Cancer, 1982, 50(10):1979-1992.
13. Wilke H, Preusser P, Fink U, et al.Preoperative chemotherapy in locally advanced and nonresectable gastric cancer:a phaseⅡstudy with etoposide, doxorubicin, and cisplatin[J].J Clin Oncol, 1989, 7(9):1318-1326.
14. Plukker JT, Mulder NH, Sleijfer DT, et al.Chemotherapy and surgery for locally advanced cancer of the cardia and fundus:phaseⅡstudy with methotrexate and 5-fluorouracil[J].Br J Surg, 1991, 78(8):955-958.
15. Mai M, Takahashi Y, Fujimoto T, et al.Neoadjuvant chemotherapy for far-advanced gastric carcinoma[J].Gan To Kagaku Ryoho, 1994, 21(4):431-439.
16. Wilke H, Stahl M, Fink U, et al.Preoperative chemotherapy for unresectable gastric cancer[J].World J Surg, 1995, 19(2):210-215.
17. Kang YK, Choi DW, Im YH, et al.A phaseⅢrandomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer[J].Proc Am Soc Clin Oncol, 1996, 15:Abstract 503.
18. Earle CC, Maroun JA.Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients:Revisiting a meta-analysis of randomised trials[J].Eur J Cancer, 1999, 35(7):1059-1064.
19. Songun I, Keizer HJ, Hermans J, et al.Chemotherapy for operable gastric cancer:results of the Dutch randomised FAMTX trial.The Dutch Gastric Cancer Group (DGCG)[J].Eur J Cancer, 1999, 35(4):558-562.
20. Fujii M, Kosaki G, Tsuchiya S, et al.Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer[J].Proc Am Soc Clin Oncol, 1999, 18:Abstract 1045.
21. Kollmannsberger C, Quietzsch D, Haag C, et al.A phaseⅡstudy of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer[J].Br J Cancer, 2000, 83(4):458-462.
22. Gianni L, Panzini I, Tassinari D, et al.Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer[J].Ann Oncol, 2001, 12(8):1179-1180.
23. Schuhmacher CP, Fink U, Becker K, et al.Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum.Closing results after 5 years of follow-up[J].Cancer, 2001, 91(5):918-927.
24. Piessen G, Messager M, Le Malicot K, et al.PhaseⅡ/Ⅲmulticentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomasPRODIGE 19-FFCD1103-ADCI002[J].BMC Cancer, 2013, 13:281.
25. Mirza A, Pritchard S, Welch I.The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas[J].Int J Surg Oncol, 2013, 2013:781742.
26. Basi A, Sohrabkhani S, Zamani F, et al.Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer[J].Int J Hematol Oncol Stem Cell Res, 2013, 7(4):24-28.
27. Schuhmacher C, Gretschel S, Lordick FA, et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European organisation for research and treatment of cancer randomized trial 40954[J].J Clin Oncol, 2010, 28(35):5210-5218.
28. Allum W, Cunningham D, Weeden S, et al.Perioperative chemotherapy in operable gastric and lower oesophageal cancer:A randomised, controlled trial (the MAGIC trial, ISRCTN 93793971)[J].Proc Am Soc Clin Oncol, 2003, 22:Abstract 998.
29. Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med, 2006, 355(1):11-20.
30. Cunningham D, Rao S, Starling N, et al.Randomised multicentre phaseⅢstudy comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer:The REAL 2 trial[J].J Clin Oncol (Meeting Abstracts), 2006, 24(18_suppl):LBA4017.
31. Du Y, Cheng XD, Xu ZY, et al.D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction[J].Chin J Cancer Res, 2013, 25(4):479-481.
32. 季加孚, 季鑫.胃癌新輔助化療的現狀與展望[J].中國腫瘤臨床, 2012, 39(20):1458-1461.
33. 肖鳳, 劉彬, 高紅英, 等.進展期胃癌新輔助化療療效的Meta分析[J].重慶醫學, 2012, 41(25):2591-2594.
34. Chen WJ, Shen J, Pan T, et al.FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer[J].Exp Ther Med, 2014, 7(2):461-467.
35. Zhao Q, Li Y, Tian Y, et al.Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma[J].Hepato-gastroenterology, 2013, 60(123):638-640.
36. 李濤, 馮道夫, 梁美霞, 等.進展期胃癌應用SOX方案新輔助化療對腫瘤TNM分期的影響[J].世界華人消化雜志, 2014, 22(2):249-252.
37. 劉林, 楊新輝, 王海江, 等.多西他賽聯合奧沙利鉑及替吉奧治療進展期胃癌的療效及對圍手術期影響[J].中國腫瘤臨床, 2014, 40(13):788-791.
38. Yoshikawa T, Rino Y, Yukawa N, et al.Neoadjuvant chemotherapy for gastric cancer in Japan:a standing position by comparing with adjuvant chemotherapy[J].Surg Today, 2014, 44(1):11-21.
39. 沈琳.進展期胃癌新輔助化療研究與實踐[J].外科理論與實踐, 2008, 13(1):21-23.
40. Arkenau HT, Saggese M, Lemech C.Advanced gastric cancer:is there enough evidence to call second-line therapy standard?[J].World J Gastroenterol, 2012, 18(44):6376-6378.
41. Shrikhande SV, Barreto SG, Talole SD, et al.D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy[J].World J Surg Oncol, 2013, 11:31.
42. Ninomiya Y, Yanagisawa A, Kato Y, et al.Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy[J].J Cancer Res Clin Oncol, 1999, 125(12):699-706.
43. Becker K, Mueller JD, Schulmacher C, et al.Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J].Cancer, 2003, 98(7):1521-1530.
44. Ott K, Weber WA, Lordick F, et al.Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction[J].J Clin Oncol, 2006, 24(29):4692-4698.
45. Lordick F, Ott K, Krause BJ, et al.PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:the MUNICON phaseⅡtrial[J].Lancet Oncol, 2007, 8(9):754-755.
46. Zhang CH, Li GL, Fan CG, et al.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer[J].World J Surg Oncol, 2012, 10:162.
47. An JY, Kim HI, Cheong JH, et al.Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy[J].Yonsei Med J, 2013, 54(4):888-894.
48. Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment[J].Cancer, 1981, 47(1):207-214.
49. Therasse P, Arbuck SG, Eisenhauer EA, et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J].J Natl Cancer Inst, 2000, 92(3):205-216.
50. Japanese Gastric Cancer Association.Japanese classification of gastric carcinoma 2nd English edition:response assessment of chemotherapy and radiotherapy for gastric carcinoma:clinical criteria[J].Gastric Cancer, 2001, 4(1):1-8.
51. Choi H, Charnsangavej C, Faria SC, et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:Proposal of new computed tomography response criteria[J].J Clin Oncol, 2007, 25(13):1753-1759.
52. Yun M, Lim JS, Noh SH, et al.Lymph node staging of gastric cancer using 18F-FDG PET:a comparison study with CT[J].J Nucl Med, 2005, 46(10):1582-1588.
53. Kwee RM, Kwee TC.Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer[J].World J Gastroenterol, 2014, 20(7):1650-1656.
54. Schuhmacher C, Reim D, Novotny A.Neoadjuvant treatment for gastric cancer[J].J Gastric Cancer, 2013, 13(2):73-78.
55. 嚴超, 朱正綱, 燕敏, 等.內鏡超聲檢查和多層螺旋CT對胃癌淋巴結轉移狀況的評估價值[J].中華外科雜志, 2005, 43(3):174-176.
56. Hwang SW, Lee DH, Lee SH, et al.Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography[J].J Gastroenterol Hepatol, 2010, 25(3):512-518.
57. Napieralski R, Ott K, Kremer M, et al.Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients[J].Clin Cancer Res, 2005, 11(8):3025-3031.
58. Ott K, Vogelsang H, Marton N, et al.The thymidylate synthase tandem repeat promoter polymorphism:A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer[J].Int J Cancer, 2006, 119(12):2885-2894.
59. Nio Y, Koike M, Omori H, et al.A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study[J].Anticancer Res, 2004, 24(3b):1879-1887.
60. Kang Y, Ohtsu A, Van Cutsem E, et al.AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)[J].J Clin Oncol (Meeting Abstracts), 2010, 28(18_suppl):LBA4007.
61. 王震, 陳俊強.進展期胃癌新輔助化療相關研究的新進展[J].中國普通外科雜志, 2012, 21(4):456-461.
62. Lorenzen S, Blank S, Becker K, et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol, 2011, 29(15, S):2119-2127.
63. Kurokawa Y, Shibata T, Sasako M, et al.Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A)[J].Gastric Cancer, 2014, 17(3):514-521.

Previous Article
Investigation of Intestinoseminal Vesicle Fistula

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content